key: cord-0974760-po1bkmo7
authors: Dherange, Parinita; Lang, Joshua; Qian, Pierre; Oberfeld, Blake; Sauer, William H.; Koplan, Bruce; Tedrow, Usha
title: Arrhythmias and COVID-19: A review
date: 2020-08-10
journal: JACC Clin Electrophysiol
DOI: 10.1016/j.jacep.2020.08.002
sha: 7a9c83d35cbc37227b37b2846dd7ecb241e42642
doc_id: 974760
cord_uid: po1bkmo7

Abstract: Current understanding of the impact of COVID-19 on arrhythmias continues to evolve as new data emerges. Cardiac arrhythmias are more common in critically ill COVID-19 patients. The potential mechanisms that could result in arrhythmogenesis among COVID-19 patients includes hypoxia caused by direct viral tissue involvement of lungs, myocarditis, abnormal host immune response, myocardial ischemia, myocardial strain, electrolyte derangements, intravascular volume imbalances and drug sides effects. To manage these arrhythmias, it is imperative to increase the awareness of potential drug-drug interactions, to monitor QTc prolongation while receiving COVID therapy and provide special considerations for patients with inherited arrhythmia syndromes. It is also crucial to minimize exposure to COVID-19 infection by stratifying the need for intervention and using telemedicine. As COVID-19 infection continues to prevail with a potential for future surges, more data is required to better understand pathophysiology and to validate management strategies.

• Cardiac arrhythmias are more common in critically ill COVID-19 patients

• Arrhythmias occur not only as a result of direct viral effect but also due to systemic illness and drug interactions.

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) which causes coronavirus disease 2019 (COVID- 19) was first officially reported in Wuhan, Hubei Province in China on 31

Dec 2019 (1) . Spreading rapidly, COVID-19 has now been classified as a pandemic with farreaching impact on the world's health and economic sectors. Millions of coronavirus cases have been reported so far (2) and several efforts are underway to better define the epidemiology of the disease (3) . While many cases remain asymptomatic, the most common symptoms include cough, fever, and fatigue. A minority of patients experience complications such as acute respiratory distress syndrome (ARDS) and other end organ damage (4) . Of particular concern is cardiac injury, defined as elevation of high sensitivity troponin I above the 99th percentile, which appears common. One case series of 146 hospitalized COVID-19 patients in China reported an cardiac injury incidence of 20% and a higher mortality of 51.2% compared to 4.5% in patients with cardiac injury versus without cardiac injury (5) . Similarly in another case series, cardiac injury was manifested in 27.8% of 187 COVID-19 patients and presence of cardiac injury was associated with fatal outcomes with a significantly higher mortality of 59.6 % compared to patients without cardiac injury (8.9%) (6) . In an observational cohort study of German patients who recently recovered from COVID-19 illness and underwent cardiac magnetic resonance with a median duration of 71 days since COVID-19 diagnosis, were found to have cardiac involvement in 78% of the patients and ongoing inflammation in 60% of the patients irrespective of the severity and overall course of the illness (7) . One aspect of cardiac injury and overall critical illness is an increased risk for cardiac arrhythmias. In this review, we present the current state of knowledge in the potential mechanism and manifestations of cardiac arrhythmias in J o u r n a l P r e -p r o o f 6 COVID-19 infected patients to provide a resource for clinicians during this rapidly evolving crisis.

Data on arrhythmia from previous epidemics and the current COVID-19 outbreak Since we currently have limited data on the current SARS-CoV-2 outbreak, it is worthwhile to understand from previous historic coronavirus epidemics due to SARS-CoV and MERS-CoV. In a case series of 121 patients diagnosed with SARS-CoV syndrome, 71.9% were found to have tachycardia independent of hypotension and fever and 14.9% were found to have bradycardia as a transient event (8) . Tachycardia was not further characterized into arrhythmias although one patient was found to have transient atrial fibrillation. It was noted that the tachycardia persisted in 40% of patients at follow up after discharge. In a case series of 70 patients with laboratory confirmed MERS-CoV in 2014 in Saudi Arabia, cardiac arrhythmias including tachyarrhythmias and severe bradyarrhythmia requiring temporary pacemaker occurred in 15.7% of patients (9) .

Though influenza belongs to a different family of viruses, it is worthwhile to note its role in arrhythmias as both COVID-19 and influenza are believed to cause myocarditis and arrhythmias (10) . Influenza has been noted to cause various tachyarrhythmias, heart block, and ventricular fibrillation, though most have been presumed to be secondary to myocarditis (11) . A surveybased study conducted by Madjij et al., patients with implantable cardiac defibrillator (ICD) or cardiac resynchronization therapy defibrillator were noted to have more ICD shocks delivered during influenza season than during other periods of the year. Also, patients with high influenza activity were reported more likely to have a ventricular arrhythmia treated with shock and with anti-tachycardia pacing (12) .

J o u r n a l P r e -p r o o f 7 Our initial understanding on incidence of arrhythmias in SARS-CoV-2 outbreak was from retrospective studies from Wuhan, China. In a case series of 137 patients of coronavirus in tertiary hospitals in the Hubei province in China, nearly 7.3% reported palpitations as the initial symptoms (13) . In another similarly sized study, 16.7% of patients were reported to have arrhythmias, with a higher incidence of 44.4% Vs 6.9% in ICU patients compared to non-ICU patients (14) . A low prevalence of arrhythmias is noted among clinically stable COVID-19 patients in a single day snapshot survey-based data (15) . A case series by Guo et al reported an occurrence of 5.9% of sustained episodes of ventricular tachycardia/ventricular fibrillation in 187 hospitalized COVID-19 patients (6) .

The data on arrhythmia characterization in COVID-19 patients in the US is now emerging. In a retrospective case series involving 393 COVID-19 patients admitted in 2 hospitals in New York City, 28 patients (7.1%) were found to have atrial arrhythmias whereas only 1 patient who was mechanically ventilated (0.3%) had ventricular arrhythmias (16) . With the current data, arrhythmias are noted to be more frequent in critically ill patients. Among 115 COVID-19 patients, atrial arrhythmias were noted in 16.5% of the patients which were all admitted to the intensive care unit (17) .

There are several manifestations of arrhythmias observed in COVID-19 patients.

Bradyarrhythmias have been described by several authors in the literature. A case of transient complete heart block requiring cardiopulmonary resuscitation was reported in a patient with COVID-19 (18) . Another case of transient high-grade atrioventricular block was reported which was thought to be as a result of subclinical myocarditis (19) . In a case series by He et al, one of the two patients with COVID-19 disease was found to have transient complete heart block along J o u r n a l P r e -p r o o f 8 with temporary occurrence of S1Q3T3 which suggests transient pulmonary artery hypertension secondary to ARDS (20) . Along with cases of bradyarrhythmias, tachyarrhythmias including atrial fibrillation, atrial flutter, supraventricular tachycardias as well as ventricular arrhythmias has been reported in patients with COVID-19 disease. A case of multifocal ventricular tachycardia was preceded by ECG findings of ST elevation in a patient with COVID-19 disease (20) . A case of acute bilateral pulmonary embolism in a COVID-19 patient later developed sustained monomorphic ventricular tachycardia with syncope requiring cardioversion (21) . Also, some of the "repurposed drugs'' used for the management of COVID-19 disease have known risk of QTc prolongation which could lead to torsades de pointes (TdP) (22) . Brugada-like ECG pattern on presentation was reported in a COVID-19 case who later had a brief episode of supraventricular tachycardia (23) . A case of atrial flutter with 2:1 AV block was seen as the presenting rhythm in a male with symptoms of COVID-19 disease who was later tested to be positive for the novel coronavirus (24) .

A recent case series published from New York highlights cases of cardiac arrhythmias in COVID-19 infection which includes high grade AV block, new onset atrial fibrillation, polymorphic ventricular tachycardia due to a ventricular premature contraction causing a longshort sequence and a case of cardiac arrest with pulseless electrical activity (25) . These manifestations suggest various potential mechanisms for arrhythmogenesis.

Possible mechanism for arrhythmogenesis Numerous potential mechanisms increase the risk of cardiac arrhythmias during COVID-19

infection. These include various modes of injury to myocardium as well as extracardiac processes that can exacerbate arrhythmias in patients with a preexisting proclivity. In the setting J o u r n a l P r e -p r o o f 9 of a viral infection, chronic cardiovascular diseases can become unstable due to increased metabolic demand and reduced cardiac reserve (26) . This imbalance, in association with direct myocardial damage and increased inflammatory response, could increase the risk of acute coronary syndrome, heart failure and cardiac arrhythmias (27, 28) . Arrhythmias in COVID-19 may result either primarily due to hypoxia caused from direct viral tissue involvement of lungs, myocarditis, abnormal host immune response or secondarily as a result of myocardial ischemia, myocardial strain due to pulmonary hypertension, electrolyte derangements, intravascular volume imbalances and drug side effects. Arrhythmias are not merely due to the direct effect of COVID-19 infection but are likely as a result of systemic illness (29) . The potential mechanisms of arrhythmia in COVID-19 are outlined in Figure 1 .

The progression of COVID-19 disease has been hypothesized to be across three overlapping yet distinct stages. This includes stage 1 for early infection with constitutional symptoms, stage 2 in which there is viral entry and replication in the type II pneumocytes causing direct viral cytotoxicity and activation of inflammatory immune response leading to ARDS and hypoxia. If the immune response is unable to clear the virus in a productive and protective fashion, stage 3 ensues which is a hyperinflammatory state and there is multiorgan dysfunction due to a cytokine storm (10).

Acute respiratory failure as a result of lung injury from novel coronavirus infection can lead to hypoxia. Following from our understanding of hypoxia induced cellular damage as it is rooted in myocardial ischemia due to coronary occlusion, hypoxia can activate anaerobic glycolysis, reducing intracellular pH and thus increasing cytosolic calcium levels. This, in turn, can facilitate early and late depolarizations, as well as cause and temporal alterations in the action potential duration (30) . Hypoxia also causes an increase in the extracellular potassium levels which decreases the threshold for depolarization, accelerating electrical conduction (30) . Additionally, Hypoxemia can also cause reduced electrical coupling and tissue anisotropy due to dephosphorylation of connexin-43 in the gap junctions (31) .

SARS-CoV-2 myocarditis has been reported several times in the literature so far (32, 33) . The proposed mechanism for the pathophysiology of myocarditis includes direct myocardial injury as a consequence of direct viral tissue involvement (34) or due to extrapulmonary migration of infected alveolar macrophages and can potentially predispose to enhanced arrhythmic risk by disrupting electrical conduction (30) . SARS-CoV-2 virus utilizes the spike protein to bind to ACE2 receptors on the myocardial cell membrane (35) . In theory, when the SARS-CoV-2 virus attaches to the ACE2 receptors found on the myocardium, there is down-regulation of the ACE2 receptors which causes unopposed angiotensin II accumulation leading to adverse myocardial remodeling by its action on Angiotensin II type 1 receptors (36) . Intracellular presence of the virus also inhibits stress granule formation via its accessory protein promoting its replication and Endomyocardial biopsy demonstrated cytopathic interstitial inflammatory cells but no viral particles were observed in the myocyte. This observation suggests myocardial localization was J o u r n a l P r e -p r o o f 12 either due to a viremia phase or due to migration of infected alveolar macrophages in extrapulmonary tissues (39) .

Along with a direct role in myocardial injury (40) , cytokines including IL-6, TNF-α, IL-1 can modulate the expression and function of potassium and calcium channels (inflammatory cardiac channelopathies) and cause prolongation of ventricular action potential (41, 42) . Inflammatory cytokines are a well-studied trigger for arrhythmia, especially in Long QT syndrome patients due to overactivation of the cardiac sympathetic system using the hypothalamus-mediated inflammatory reflex and peripheral-mediated activation of stellate ganglion pathway (43) which can lead to QT prolongation (44) . Furthermore, IL-6 inhibits CYP450 which increases the bioavailability of QT prolonging drugs (45) .

Potential causes for myocardial ischemia are microvascular dysfunction and hyperinflammatory state leading to activation of inflammatory cells within a pre-existing atherosclerotic plaque causing vasoconstriction due to dysregulation of the coronary vascular endothelial function. In one study, microvascular dysfunction was found to be in the form of disseminated intravascular coagulation (DIC) due to hyper inflammation and immune activation (46) . IL-6 and TNF-α can cause both depletion of coagulation and fibrinolytic system leading to bleeding as well as thrombosis (47) . The other postulated mechanism of microvascular dysfunction causing myocardial ischemia is via infection-mediated vasculitis. SARS-CoV-2 virus attach to the ACE receptors which are also expressed in arterial and venous endothelial cells (48) . Vasculitis can J o u r n a l P r e -p r o o f 13 thus be triggered either as a result of hypersensitivity reaction induced due to direct viral entry in the myocardial endothelial cells or due to indirect immunological response (49) . Myocardial injury with ST segment elevation has also been reported in patients with COVID-19 infection (50) . Cytokine surge and the inflammatory mediators can also cause acute coronary syndrome due to activation of inflammatory cells within a pre-existing atherosclerotic plaque as well as vasoconstriction due to dysregulation of the coronary vascular endothelial function (51) .

Pathogen-associated molecular patterns (PAMPs) are formed with viral products in the systemic circulation which can cause activation of innate immune response as well as activation of inflammasome resulting in the formation of biologically active cytokines (52) .

Right myocardial strain can be seen as a result of pulmonary embolism which has been reported as the most common thrombotic complication in COVID-19 patients(53) or due to pulmonary hypertension causing increased right sided pressures secondary to severe ARDS, sepsis or heart failure (54) . Increased right atrial pressure along with increased sympathetic tone in patients with pulmonary hypertension and hypoxia can predispose to increased risk of atrial tachyarrhythmias (55) . On the other hand, a case of temporary occurrence of S1Q3T3 which has been previously described in this review was found to have transient complete heart block suggested to be due to transient pulmonary artery hypertension (20) .

Arrhythmias due to electrolyte abnormalities as well as its effect on pre-existing arrhythmias has been well studied (56) . In a case series, electrolyte disturbances were reported in 7. infection (57) . A case report of a COVID-19 patient presenting with atrial arrhythmias previously described in this review, was noted to have severe electrolyte disturbances including hypokalemia, hypomagnesemia and hypophosphatemia (24) .

Fluid disturbances are commonly encountered in critically ill patients. Intravascular volume imbalances in COVID-19 disease could either be ascribed to sepsis caused from ARDS or due to heart failure. The most commonly encountered arrhythmia in the critical care setting which can be caused due to the above described mechanism among others, is atrial fibrillation (58) .

Many of the "off-label" COVID-19 therapies including hydroxy(chloroquine), lopinavir/ritonavir and azithromycin have either known or possible risk of torsades de pointes (TdP) due to their effect on QT prolongation (59) . Hydroxy(chloroquine) and azithromycin inhibit hERG-K+ channel which causes prolongation of action potential, and this along with unopposed inward Na+ and Ca2+ currents trigger early after depolarization that can lead to TdP. In a cohort study of 90 hospitalized COVID-19 patients, the administration of hydroxychloroquine with or without azithromycin was associated with an increased risk of QTc prolongation and risk of TdP (60).

Antimalarial drugs hydroxy(chloroquine) not only can cause this fatal side effect of QT prolongation but can also cause advanced atrioventricular conduction block (28) . Currently, there 

Identify and treat secondary causes of atrial tachyarrhythmias like hypoxia, metabolic and electrolyte imbalances, proarrhythmic effect of drugs, or myocardial ischemia.

In patients with supraventricular tachycardia, intravenous adenosine can be used for acute termination although further validation is needed. Electrical cardioversion can be considered in patients with refractory cases and should be postponed in stable and asymptomatic patients. One should have a low threshold to initiate maintenance therapy with beta blockers (BBs) or calcium channel blockers (CCBs) if BBs are contraindicated; however, BB and CCB drug interactions with antiviral drugs should be evaluated prior to starting these medications to avoid bradycardia and QT prolongation (61, 62) .

In patients with recurrent atrial fibrillation (AF) and Atrial Flutter (AFl) who are hemodynamically stable, consider discontinuing antiarrhythmic drugs (AAD) especially sotalol, flecainide and likely amiodarone and propafenone given serious drug-drug interactions with antiviral drugs and to start rate controlling medications with BBs or CCBs unless contraindicated, with or without digoxin. Similarly, patients with new onset of AF/AFl with a stable rhythm can be treated with rate control. Rhythm control strategy should be reserved for patients with hemodynamically unstable patients or in congestive heart failure patients (61, 62) .

There is a high risk of immediate recurrence of arrhythmia without the use of any AAD as maintenance therapy, which can be minimized by treating secondary causes of arrhythmias prior to attempting rhythm control strategy. 

In patients with Long QT syndrome (LQTS), monitor QT interval and cardiac rhythm due to high risk of QT prolongation seen in COVID-19 disease. Hypokalemia should be avoided in patients with COVID-19 associated diarrhea. It is recommended to maintain a potassium level at the higher range of normal. The effect of fever is not much evident with LQTS (except with specific LQTS2 mutation). Whereas in patients with brugada syndrome (BrS), fever can unmask the ECG manifestation of type 1 BrS and thus it is recommended that all patients with COVID- 

Experimental drugs used for treatment of COVID-19 hold a significant risk for QTc prolongation. A case series by Ramireddy et al reported an increase in QTc in 12% of patients receiving hydroxychloroquine, azithromycin or both; however, no TdP was seen (67) . In a randomized controlled trial (CloroCOVID-19 trial) studying the effect of low dose (450 mg twice daily for one day, then 450 mg daily for four days) versus high dose (600 mg twice daily for 10 days) chloroquine in addition to azithromycin in severe COVID-19 patients showed lethality in the higher dose group with an odds ratio of 3.6 (95% CI, 1.2-10.6) and thus recommended against the use of high dose of chloroquine in severe cases (68) . Traditionally Tisdale risk score which has been used to calculate the risk for QTc prolongation in hospitalized patients, could also be used to risk stratify COVID-19 patients with a goal to aggressively monitor increased risk patients (69) . It consists of age ≥ 68 yrs, female sex, use of loop diuretics, potassium level ≤ 3.5 mEq/L, baseline QTc ≥ 450 ms, acute MI, number of QT prolonging J o u r n a l P r e -p r o o f 20 medications, sepsis, and heart failure. A score of ≤ 6 predicts low risk, 7-10 medium risk, and ≥ 11 high risk of drug-associated QT prolongation (70) .

An algorithm (59) (72) . Class 1B antiarrhythmic agents, due to its effect on the late sodium current by blocking the INa-L channel, have been shown to slightly shorten the QT interval and suppress TdP in acquired LQTS. Other known therapies to alleviate risk of TdP, such as maintaining potassium and magnesium levels and heart rates > 70 beats per minute have also been described (72) .

Another important consideration during management of COVID-19 patients is drug-drug interaction in the treatment of COVID-19, especially with concomitant use of antiarrhythmics and anticoagulants. For instance, the levels of hepatically eliminated antiarrhythmic drugs including amiodarone, propafenone, flecainide, quinidine and some novel oral anticoagulants including apixaban, rivaroxaban which are metabolized mainly by different cytochrome P450 (CYP) isoenzymes (e.g. CYP3A4, CYP2C9), can be increased by co-administration of Lopinavir/ritonavir as it inhibits CYP3A4 (66, 73) . Table 1 summarizes the potential interactions of drugs used for COVID-19 therapy with cardiac drugs.

In the COVID-19 pandemic, the US healthcare system may face another huge challenge due to shortage of personal protective equipment (PPE), which are routinely used by health care providers to protect themselves from infectious conditions and toxic substances. The fundamental goal is to avoid elective procedures in order to conserve precious resources like PPE and hospital beds and also minimize unnecessary exposure to COVID-19. A practical guide from a New York City Hospital Network describes an approach used to overcome these challenges testing availability or with concern for community spread, it may be prudent to consider at least droplet precautions for all EP procedures. N95 masks should be used by all operating physicians and a surgical mask for all patients (74) . If needing intubation which is an aerosol generating procedure, it is recommended to consider performing in a negative pressure room either in the EP lab or inpatient ICU before bringing the patient to EP lab. Anesthesia data recommends to limit personnel in the procedure room during intubation or extubation and to follow institutional protocols for the length of time before other personnel can return to the room after intubation which could be between 15-30 minutes based on frequency of air exchanges and the type of PPE used (76) . Conscious sedation can be considered by EP attending with backup anesthesia services without compromising patient safety (74) . Electrocautery is another aerosol generating procedure which is routinely used during device implantation procedures and the smoke produced can have a significant amount of viral load. Surgical data recommend using low power electrocautery settings and using adequate PPE including goggles or face shield for eye protection as it is considered possible that SARS-COV-2 virus can be transmitted to the J o u r n a l P r e -p r o o f 23 conjunctiva by aerosol although there is no evidence (77) . Plasmablade is a soft tissue dissection device other than electrocautery which is routinely used especially during generator changes to limit lead damage, produces less smoke and in theory could be used as a substitute for electrocautery however there is no evidence to support this. Apart from considerations for EP procedures, the HRS COVID-19 task force document (75) also provides guidance regarding management of patients in the outpatient setting via telemedicine as well as regarding minimizing in-person CIED interrogation via remote device monitoring.

Our understanding of the impact of COVID-19 on arrhythmias continues to evolve as new data emerges. Current data suggests that arrhythmias are more frequent in the critical care settings.

The increasing risk of arrhythmias in COVID-19 patients is likely as a result of systemic illness and not merely as a result of direct effect of the viral infection. To manage arrhythmias in patients with COVID-19, it is imperative to increase the awareness of potential drug-drug interactions, to monitor QTc prolongation while receiving COVID therapy and provide special considerations for patients with inherited arrhythmia syndromes. It is also crucial to minimize exposure to COVID-19 infection by stratifying the need for intervention and using telemedicine.

As COVID-19 infection continues to prevail with a potential for future surges, more data is required to better understand pathophysiology and to validate management strategies. 

-↓ in HR, ↑ PR interval, ↑↑ in QTc interval with very low risk of TdP.

-AAD drug interactions:

WHO IHR Emergency Committee for the COVID-19 Outbreak

Johns Hopkins Coronavirus Resource Center

Defining the Epidemiology of Covid-19 -Studies Needed

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia

Cardiovascular complications of severe acute respiratory syndrome

Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single

COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies. JACC: Basic to Translational Science

The cardiovascular manifestations of influenza: a systematic review

Effect of High Influenza Activity on Risk of Ventricular Arrhythmias Requiring Therapy in Patients With Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Low prevalence of arrhythmias in clinically stable COVID-19 patients

Clinical Characteristics of Covid-19 in New York City

Atrial Arrhythmias in COVID-19 Patients

Transient complete heart block in a patient with critical COVID-19

HEART BRAKE-An unusual cardiac manifestation of Coronavirus disease 2019 (COVID-19). JACC Case Rep 2020

Characteristic ECG manifestations in patients with COVID-19

Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol

Transient Brugada-like ECG pattern in a patient with Coronavirus Disease 2019 (COVID-19). JACC Case Rep 2020

Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection

Cardiac Arrhythmias in COVID-19

Coronaviruses and the cardiovascular system: acute and long-term implications

Myocardial injury and COVID-19: Possible mechanisms

Cardiac and arrhythmic complications in patients with COVID-19

COVID-19 and Cardiac Arrhythmias

COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap! Circulation

Coronary artery disease and ventricular tachyarrhythmia: pathophysiology and treatment

Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management

Arrhythmias in myocarditis: State of the art

Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Aldosterone System Inhibitors in Patients with Covid-19

Amiodarone as a possible therapy for coronavirus infection

What Is the Arrhythmic Substrate in Viral Myocarditis? Insights from Clinical and Animal Studies

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Towards understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation: a magnetic resonance imaging study

An Emerging Role for Inflammation and Immunity

Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies

Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis

Functional distribution of right and left stellate innervation to the ventricles: production of neurogenic electrocardiographs changes by unilateral alteration of sympathetic tone

Antiarrhythmic potential of anticytokine rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Bleeding and coagulopathies in critical care

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

Endothelial cell infection and endotheliitis in COVID-19

ST-segment elevation in patients with Covid-19-A case series

Acute infection and myocardial infarction

Inflammasome activation and IL-1β and IL-18 processing during infection

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Pulmonary hypertension due to acute respiratory distress syndrome

Atrial Arrhythmias in Pulmonary Hypertension: Pathogenesis, Prognosis and Management

Role of electrolytes in etiology and management of cardiac arrhythmias

Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection n

Atrial Fibrillation in the ICU

Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19

Recommendations for the organization of electrophysiology and cardiac pacing services during the COVID-19 pandemic

American Heart Rhythm Society (LAHRS) in collaboration with: Colombian College Of Electrophysiology, Argentinian Society of Cardiac Electrophysiology (SADEC), Brazilian Society Of Cardiac Arrhythmias (SOBRAC), Mexican Society Of Cardiac Electrophysiology (SOMEEC)

Guidance on Acute Management of Atrial Fibrillation in COVID-19

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Coagulation abnormalities and thrombosis in patients with COVID-19

SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes

Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring n

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Ventricular Arrhythmia Risk Due to Chloroquine/Hydroxychloroquine Treatment For COVID-19: should it be given

Ventricular arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19

Multi-lead QT Screening is Necessary for QT Measurement: Implications for Management of Patients in the COVID-19

Clinical Electrophysiology

An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation

Restructuring Electrophysiology During the COVID-19 Pandemic: A Practical Guide from a New York City Hospital Network

Guidance for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology

Post-Aerosol Pause" for Patients Under Investigation or Positive for COVID-19

COVID-19 coronavirus: recommended personal protective equipment for the orthopaedic and trauma surgeon